Tiziana responds to UK call for innovation development
NEW YORK and LONDON, June 17, 2021 (GLOBE NEWSWIRE) – Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS), a biotechnology company focused on innovative therapies for oncology, neurology, inflammation and infectious diseases, announces that it has submitted a grant to the COVID Therapeutics Advisory Panel (UK -CTAP) from the United Kingdom to support further clinical studies developing nasally administered Foralumab, a fully human anti-CD3 monoclonal antibody, as’Bring back home’ approach for the treatment of outpatients with COVID-19. This is in response to a UK government call for proposals to investigate therapies that can be administered at home and avoid hospitalization of patients.
Nasal administration of Foralumab is a very innovative approach to treat patients with autoimmune diseases where the immune system may be deregulated. Several studies have suggested that there is a disruption of the immune system in patients with Covid-19 disease. Previously, we announced the successful clinical study with Foralumab administered nasally in patients with COVID-19 in Brazil. The results of this study demonstrated that the treatment induced immunomodulatory effects capable of providing clinical benefit to Covid-19 patients. It is important to note that the direct administration of Foralumab using a nasal spray ‘Bring back home’ device in the nasal passages and airways rapidly suppressed lung inflammation, as evidenced by CT scans and reduced systemic markers of inflammation including interleukin-6 and C-reactive protein (https: / /www.tizianalifesciences.com/news-item?s= 2021-02-02-tiziana-positive-reports-data-from-clinical-study-of-nasal-administration-with-foralumab-its-owner -full-human-anti-cd3-monoclonal-antibody-in-covid-19-patients-in-brazil). These clinical results justify the continued clinical development of Foralumab administered by the nasal route in patients with Covid-19.
Separately, Tiziana Life Sciences is also completing processes to launch another COVID-19 inpatient clinical trial in Brazil. The objective of this study is to assess whether Foralumab administered by the nasal route could be useful for hospitalized patients with severe inflammation. Since nasal administration with Foralumab is an immunomodulatory approach, it is possible that this ‘on-the-go’ treatment approach may be useful for the treatment of other COVID-19 variants, including variants identified in South Africa. , Brazil, UK and the Delta variant in India.
About Tiziana Life Sciences
Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS) is a British biotechnology company focused on the discovery and development of new molecules to treat human diseases in oncology and immunology. In addition to Milciclib (a CDK inhibitor under development in oncology), the Company is also developing Foralumab in COVID-19, multiple sclerosis and Crohn’s disease. Foralumab is the only second generation fully human anti-CD3 monoclonal antibody in clinical development worldwide. This phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases, such as non-alcoholic steatohepatitis (NASH), ulcerative colitis, multiple sclerosis, type 1 diabetes (T1D), Crohn’s disease, psoriasis, and rheumatoid arthritis, where modulation of a T cell response is desirable. The Company is accelerating the development of anti-interleukin 6 receptor mAb (IL6R), a fully human monoclonal antibody for the treatment of IL6-induced inflammatory lung disease.
Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but are rather based on the Company’s current expectations, estimates and projections regarding its industry; his beliefs; and assumptions. Words such as “anticipates”, “expects”, “intends”, “plans”, “believes”, “research”, “estimates” and similar expressions are intended to identify forward-looking statements. . These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of the Company, are difficult to predict and could cause that actual results differ materially from those expressed or expected. in forward-looking statements. The Company cautions securityholders and potential security holders not to place undue reliance on these forward-looking statements, which only reflect the Company’s views as of the date of this announcement. The forward-looking statements contained in this announcement relate only to events that occurred on the date on which the statements are made. The Company will not undertake to publicly post revisions or updates to such forward-looking statements to reflect unforeseen events, circumstances or events occurring after the date of such announcement, except as required by law or by any authority. appropriate regulatory framework.
|For more information :|
|Tiziana Life Sciences plc|
|Gabriele Cerrone, President and Founder||+44 (0) 20 7495 2379|
|Dave Gentry, CEO|
|RedChip Companies Inc.||407-491-4498|